Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Up 65.9% in November

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 3,550,000 shares, a growth of 65.9% from the October 31st total of 2,140,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

EYEN has been the subject of a number of recent research reports. William Blair reissued a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. HC Wainwright downgraded Eyenovia from a “buy” rating to a “neutral” rating and cut their price target for the stock from $12.00 to $2.00 in a research note on Monday, November 18th. Finally, LADENBURG THALM/SH SH reiterated a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th.

Institutional Trading of Eyenovia

A number of institutional investors and hedge funds have recently modified their holdings of EYEN. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eyenovia during the second quarter valued at $26,000. Ground Swell Capital LLC bought a new stake in Eyenovia in the 2nd quarter worth about $27,000. Nations Financial Group Inc. IA ADV raised its position in Eyenovia by 24.4% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Financial Management Network Inc. bought a new position in Eyenovia during the 3rd quarter valued at about $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in shares of Eyenovia during the 2nd quarter valued at about $87,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Stock Performance

Shares of EYEN stock opened at $0.10 on Friday. The company has a market capitalization of $8.56 million, a price-to-earnings ratio of -0.14 and a beta of 1.75. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. Eyenovia has a one year low of $0.08 and a one year high of $2.57. The company’s 50-day moving average is $0.40 and its 200 day moving average is $0.66.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the previous year, the business earned ($0.18) EPS. Sell-side analysts expect that Eyenovia will post -0.5 EPS for the current fiscal year.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.